



"Impact Of Granulation Time And Drying Temperature On Compression Parameters: A Review Of Critical Process Parameters And Quality Attribute"

Rajendra Kisanrao Khodade^{1*}, Prof. Kore Kakasaheb Jagannath²

¹M. Pharm student Department of Pharmaceutics, Rajgad Dnyanpeeth College of Pharmacy, Bhore Dist.

Pune 412206

²Professor, Department of Pharmaceutics Rajgad Dnyanpeeth's College of pharmacy Bhore Dist. Pune 412206

Maharashtra India

Abstract: This review article explores the impact of granulation time and drying temperature on compression parameters and quality attributes in pharmaceutical manufacturing. Granulation and drying are critical unit operations that significantly influence the physical properties of granules, which, in turn, affect tablet characteristics such as hardness, disintegration time, and dissolution rates. The interdependence between granulation time and drying temperature is emphasized, highlighting how each parameter influences granule size, moisture content, and compressibility. Key findings indicate that insufficient granulation time can lead to poorly agglomerated granules, while excessive granulation may result in overly dense granules requiring longer drying times. Similarly, inadequate drying temperatures can cause excessive moisture retention, affecting granule flowability and compressibility, whereas high drying temperatures can lead to brittleness. The article underscores the necessity of optimizing Critical Process Parameters (CPPs) to ensure consistent Critical Quality Attributes (CQAs) and regulatory compliance. Additionally, advancements in technologies such as continuous manufacturing and Process Analytical Technology (PAT) are discussed, emphasizing their role in real-time monitoring and control of granulation and drying processes. This review serves as a comprehensive guide for researchers and industry professionals seeking to enhance product quality through the optimization of granulation and drying conditions.

Keywords: Granulation Time, Drying Temperature, Compression Parameters, CPP, CQA, PAT

I. Introduction

Granulation and Drying Processes in Pharmaceutical Manufacturing

Granulation and drying are critical processes in pharmaceutical manufacturing that significantly affect the quality of solid dosage forms, such as tablets. Both processes are essential in ensuring that the final product meets the required physical and chemical standards for safety, efficacy, and stability.

Granulation

Granulation is the process of forming small particles or powders into larger, more cohesive aggregates called granules. This process is essential in pharmaceutical production for several reasons:

- **Improved Flowability:** Granules have better flow properties than fine powders, which is critical for ensuring consistent feeding of the material into the tablet press.
- **Uniformity of Dosage:** Granulation helps to ensure that active pharmaceutical ingredients (APIs) and excipients are uniformly distributed throughout the blend, which leads to consistent drug content in each tablet.
- **Enhanced Compressibility:** Granules are more compressible than powders, making it easier to form robust tablets with the desired hardness and friability.
- **Reduction of Segregation:** Granulation minimizes the segregation of powders based on size or density, which helps in maintaining uniformity throughout the manufacturing process.

There are two main types of granulation processes:

1. **Wet Granulation:** This method involves the addition of a granulation liquid (usually water or an organic solvent) to the powder blend, followed by mixing to form a wet mass. The wet mass is then passed through a sieve or extruded to form granules.
2. **Dry Granulation:** In this method, granulation is achieved without the use of liquids. The powder blend is compacted under high pressure to form large slugs or sheets, which are then broken down into granules through milling.

Drying

Drying is the process of removing moisture or solvent from wet granules. It is an essential step following wet granulation to ensure that the granules are at the correct moisture level before further processing, such as compression into tablets.

The key roles of drying in pharmaceutical manufacturing include:

- **Moisture Control:** Proper drying is crucial to achieving optimal moisture content in the granules. Excess moisture can lead to poor flowability, sticking during compression, and tablet instability, while insufficient moisture can result in poor compressibility.
- **Granule Strength:** Drying affects the structural integrity of the granules. Controlled drying helps achieve the desired hardness and friability, which are important for producing robust tablets that do not break apart during handling or packaging.
- **Preventing Degradation:** Many APIs and excipients are sensitive to moisture, and excessive moisture can cause chemical degradation. Proper drying helps preserve the stability and potency of the drug product.

Common drying techniques used in pharmaceutical manufacturing include:

- **Fluidized Bed Drying:** In this method, air is passed through the granules, causing them to become suspended (fluidized) and resulting in efficient moisture removal.
- **Tray Drying:** Granules are spread out on trays and dried by passing heated air over them. This method is slower but can be used for heat-sensitive products.
- **Vacuum Drying:** This technique uses reduced pressure to lower the boiling point of the solvent, allowing drying at lower temperatures, which is beneficial for temperature-sensitive materials.

Both **granulation** and **drying** processes have a direct impact on the **Critical Process Parameters (CPPs)**, such as granule size distribution, moisture content, and flow properties, which ultimately influence the **Critical Quality Attributes (CQAs)** of the final product, like tablet hardness, dissolution rate, and content uniformity.

II. CRITICAL PROCESS PARAMETERS (CPP) AND CRITICAL QUALITY ATTRIBUTES (CQA)

In pharmaceutical manufacturing, Critical Process Parameters (CPP) and Critical Quality Attributes (CQA) are essential concepts for ensuring product quality, safety, and efficacy. They are central to the Quality by Design (QbD) approach, which emphasizes a deep understanding of the manufacturing process and its impact on product outcomes. Here's an explanation of each term and their significance in process development and control:

A. Critical Process Parameters (CPP)

Critical Process Parameters (CPP) are the key variables in a manufacturing process that, when within an acceptable range, directly impact the Critical Quality Attributes (CQAs) of the product. These parameters need to be carefully monitored and controlled to ensure consistent production of a high-quality drug product. Examples of CPPs in pharmaceutical manufacturing include:

- **Granulation Time:** Influences the particle size distribution, flow properties, and compressibility of granules.
- **Drying Temperature:** Affects the moisture content of granules and, consequently, the physical properties of tablets.
- **Compression Force:** Impacts tablet hardness, friability, and dissolution rate.
- **Mixing Speed:** Influences the uniformity of API distribution in the blend.

Importance: Controlling CPPs is essential because small variations in these parameters can lead to significant changes in the final product's quality attributes. By identifying and optimizing these parameters, manufacturers can prevent batch failures, reduce variability, and ensure that the final product consistently meets quality specifications.

Effective CPP control helps:

- **Minimize Risk:** Reduces the risk of producing out-of-specification products.
- **Enhance Process Understanding:** Provides insight into how different variables impact the product, leading to improved process design.
- **Enable Consistency:** Ensures that the manufacturing process remains within defined limits, leading to consistent product quality across batches.

B. Critical Quality Attributes (CQA)

Critical Quality Attributes (CQA) are the physical, chemical, biological, or microbiological characteristics of a drug product that must be maintained within specific limits to ensure the product meets its intended safety, efficacy, and performance. These attributes directly affect the patient experience and treatment outcomes.

Examples of CQAs include:

- **Tablet Hardness:** Must be within a specific range to ensure mechanical stability during transportation and handling.
- **Dissolution Rate:** Controls how quickly the drug is released into the body and absorbed, impacting its therapeutic efficacy.
- **Content Uniformity:** Ensures consistent dosage of the active pharmaceutical ingredient (API) across all tablets in a batch.
- **Moisture Content:** Excessive moisture can degrade the API, while insufficient moisture may affect tablet compressibility and disintegration.
- **Disintegration Time:** Ensures the tablet breaks down within a specified time to allow proper drug release.

Importance: CQAs are directly linked to patient safety and the therapeutic effectiveness of the drug. By ensuring these attributes are maintained within their required limits, manufacturers can guarantee that the drug will perform as intended in terms of bioavailability, stability, and safety.

The importance of controlling CQAs includes:

- **Ensuring Drug Efficacy:** CQAs like dissolution and bioavailability directly impact how well a drug performs in the patient's body.
- **Maintaining Product Safety:** Characteristics such as sterility and microbial limits are essential to preventing harmful contamination.
- **Complying with Regulatory Standards:** Regulatory authorities like the FDA and EMA require pharmaceutical companies to establish and control CQAs to meet safety and efficacy requirements.

The Relationship Between CPP and CQA

There is a direct relationship between CPPs and CQAs. CPPs are the variables that can influence CQAs during the manufacturing process. For example, variations in granulation time (CPP) can lead to differences in particle size distribution (CQA), which in turn impacts the compressibility and tablet hardness (CQA). Similarly, if drying temperature (CPP) is not controlled properly, it can result in either too much or too little moisture in the granules, affecting CQAs like disintegration time or tablet stability.

Understanding and controlling CPPs is essential to maintaining CQAs within their desired limits. A key aspect of process development and control is using tools such as Design of Experiments (DoE) and Process Analytical Technology (PAT) to identify CPPs that are critical to the final product's quality and to develop robust processes that consistently deliver products that meet predefined quality standards.

Why They Matter in Process Development and Control

- **Regulatory Compliance:** Agencies like the FDA expect manufacturers to identify and control CPPs and CQAs as part of their quality systems. This is a requirement for ensuring consistent product quality across large-scale production.
 - **Risk Management:** By identifying CPPs and CQAs, manufacturers can better predict and manage risks associated with process variability, reducing the chances of product recalls or regulatory issues.
 - **Product Optimization:** Understanding the relationship between CPPs and CQAs helps in optimizing processes for better performance, efficiency, and cost-effectiveness. For example, optimizing drying temperature can help achieve ideal moisture content while reducing drying time and energy consumption.
- Both CPP and CQA are integral to ensuring the quality, safety, and efficacy of pharmaceutical products. A well-controlled manufacturing process, informed by a deep understanding of CPPs and CQAs, is essential for delivering high-quality drugs that meet both regulatory requirements and patient needs.

III. GRANULATION TIME AS A CRITICAL PROCESS PARAMETER (CPP)

Granulation time is a key Critical Process Parameter (CPP) in pharmaceutical manufacturing, particularly in processes like wet granulation and dry granulation. The duration of the granulation process significantly impacts the physical and mechanical properties of granules, which in turn affect the final product's Critical Quality Attributes (CQAs), such as compressibility, tablet hardness, and dissolution rate.

Granulation Process Overview

Granulation is the process of agglomerating fine powder particles into larger, more cohesive granules. The purpose of granulation in tablet formulation is to improve flowability, reduce dust, enhance compressibility, and ensure uniform distribution of active pharmaceutical ingredients (APIs) and excipients.

There are two main types of granulation:

- **Wet Granulation:** Involves adding a granulating liquid to the powder mixture to form granules.
 - **Dry Granulation:** Achieved by compacting powder under high pressure without the use of liquids.
- Regardless of the method, granulation time—the time for which the powders are subjected to granulation forces—plays a critical role in determining the characteristics of the granules.

Impact of Granulation Time on Granule Properties

Granulation time affects several key characteristics of the granules, which in turn influence the final tablet properties:

1. Particle Size Distribution:

- **Short Granulation Time:** Insufficient granulation time can result in smaller, poorly agglomerated granules, leading to poor flowability, uneven distribution of the API, and difficulties in compression.
- **Extended Granulation Time:** Excessive granulation time may lead to the formation of overly large or excessively dense granules, which can cause poor compaction, slower disintegration, or tablet cracking during compression.
- Optimal granulation time is essential for achieving a uniform particle size distribution, which ensures good flow properties and uniform compression.

2. Granule Density and Porosity:

- **Under-Granulation:** If granulation time is too short, granules may not form properly, leading to poor compressibility. The granules may remain too porous, affecting tablet hardness and friability.
- **Over-Granulation:** Overextended granulation time can result in highly dense granules, reducing their ability to deform during compression. This can affect the compactibility and the binding properties of the granules, leading to hard tablets with poor dissolution profiles.
- Controlling granulation time helps ensure that granules have the right balance between density and porosity for optimal tablet formation.

1. Moisture Content (for wet granulation):

- **Short Granulation Time:** If insufficient time is allowed for the granulation liquid to evenly distribute throughout the powder, the moisture content may remain uneven, causing problems during drying and compression. This can lead to inconsistent tablet quality and content uniformity.
- **Extended Granulation Time:** Excessive time in wet granulation can lead to overwetting of the granules, which may require longer drying times and increase the risk of granule agglomeration or hardening. Over-wet granules may also stick to equipment, affecting process efficiency and increasing product losses.

2. Flowability and Compressibility:

- **Flowability:** Granulation improves the flow properties of powders by increasing the particle size and reducing dust. However, insufficient granulation time can lead to poor flowability, affecting the consistent filling of tablet dies. On the other hand, too long granulation can produce granules that are too dense or sticky, also affecting flow.
- **Compressibility:** Proper granulation time ensures that granules are compressible, leading to strong tablets that maintain their structural integrity. Poor compressibility, resulting from either under- or over-granulation, can lead to weak tablets that may crumble or break easily.

Influence on Critical Quality Attributes (CQAs)

Granulation time directly influences several Critical Quality Attributes (CQAs) of the final product:

1. **Tablet Hardness:** Granulation time affects the size, density, and moisture content of granules, all of which determine how well the tablet compacts during compression. Short or inadequate granulation time may result in weak tablets with poor hardness, while excessive granulation can lead to excessively hard tablets that may not disintegrate properly.
2. **Disintegration and Dissolution Rate:** Optimal granulation time is critical for ensuring that the granules break apart easily in the body to release the drug. Overly dense or overly large granules, formed due to prolonged granulation, can slow the tablet's disintegration and reduce the drug's dissolution rate, affecting bioavailability.
3. **Content Uniformity:** Proper granulation time ensures that the API and excipients are uniformly distributed throughout the granules, leading to uniformity in drug content across all tablets. Insufficient granulation time can result in segregation or non-homogenous granules, causing variability in the dosage.

4. **Friability:** Granulation time affects the friability (tendency to crumble) of tablets. Granules that are either too weak (from short granulation times) or too hard (from long granulation times) can lead to tablets that do not withstand handling and packaging well.

Optimization of Granulation Time: To optimize granulation time, manufacturers need to understand the interplay between granulation time and other process parameters, such as binder concentration, mixing speed, and the type of equipment used. Several tools and methodologies can aid in this optimization:

Design of Experiments (DoE): By systematically varying granulation time along with other parameters, manufacturers can identify the optimal time that balances granule size, density, moisture content, and flowability.

Real-Time Monitoring (PAT): Process Analytical Technology (PAT) tools, such as near-infrared spectroscopy (NIR), can be used to monitor the granulation process in real-time, helping to determine the exact point when granules reach their desired characteristics.

Scale-Up Considerations: During scale-up from lab-scale to production-scale, granulation time may need to be adjusted based on equipment size and operational differences. Manufacturers must carefully monitor and control this parameter to ensure consistent quality across different scales of production.

IV. DRYING TEMPERATURE AS A CRITICAL PROCESS PARAMETER (CPP)

Drying temperature is a key Critical Process Parameter (CPP) in pharmaceutical manufacturing, particularly following wet granulation. The temperature at which granules are dried directly impacts the quality of the final product by influencing moisture content, granule strength, flowability, and compressibility. Effective control of drying temperature is essential for ensuring that the product's Critical Quality Attributes (CQAs) are within specification, particularly in terms of stability, tablet strength, and dissolution behavior.

A. Role of Drying in Pharmaceutical Manufacturing

After the wet granulation process, the granules contain residual moisture that needs to be removed to prevent issues during further processing such as compression, packaging, and storage. The purpose of drying is to achieve the desired level of residual moisture, which is critical to the product's physical and chemical stability.

Drying processes can vary, but the two most common methods are:

1. **Fluidized Bed Drying:** Air is blown through the granules, causing them to become fluidized, which promotes efficient drying through increased surface area exposure.
2. **Tray Drying:** Granules are spread on trays, and heated air is passed over them. This is a slower process but can be used for heat-sensitive products.

B. Impact of Drying Temperature on Granule Properties

1. Moisture Content:

- **High Drying Temperature:** Higher drying temperatures can lead to rapid moisture removal. While this may speed up the drying process, it risks creating overly dry or brittle granules, which may lead to poor compressibility and excessive dusting. Additionally, too high a temperature can result in thermal degradation of sensitive active pharmaceutical ingredients (APIs) or excipients.
- **Low Drying Temperature:** Drying at too low a temperature can leave residual moisture in the granules, leading to poor flowability, sticking issues during compression, and potential stability problems in the final product due to the presence of moisture.

Achieving the right drying temperature is critical for maintaining the optimal moisture content in granules, which ensures they are neither too dry nor too wet for subsequent processing.

2. Granule Strength and Compressibility:

- **High Temperature:** Excessive drying can make the granules too hard or brittle, leading to difficulties during compression. Hard granules may resist deformation under pressure, resulting in tablets that are weak and prone to breaking or exhibiting poor mechanical integrity.

- **Low Temperature:** Inadequate drying may leave granules too soft or weak, affecting their ability to compress into solid, durable tablets. Such granules may form tablets that are too soft or friable, prone to crumbling during handling or packaging.
- 3. **Flowability:**
 - **High Temperature:** Over-dried granules may become too light and dusty, reducing their flowability. Poor flow can lead to inconsistent die filling during tablet compression, resulting in weight variability and dosage inconsistency.
 - **Low Temperature:** Underdried granules tend to be sticky and may clump together, leading to poor flowability and challenges during compression. Sticky granules can also cause issues with equipment, such as sticking to the tablet press, leading to production inefficiencies.
- 4. **Particle Size and Distribution:**
 - **High Temperature:** Excessive drying may cause shrinkage or particle aggregation, leading to uneven granule sizes. This can result in poor flow properties and affect the uniformity of tablet weight and API distribution.
 - **Low Temperature:** If the drying is insufficient, granules may retain excess moisture, which can lead to particle agglomeration or improper breakage during subsequent milling, affecting size distribution.

C. Influence on Critical Quality Attributes (CQAs)

1. **Tablet Hardness:** Drying temperature directly affects the mechanical properties of the granules. Over-dried granules may be too hard and lead to excessively hard tablets, while under-dried granules may compress poorly, resulting in soft or fragile tablets. Both extremes can affect tablet integrity, handling, and packaging.
2. **Disintegration and Dissolution Rate:** Granules with the right moisture content will form tablets that disintegrate properly. Overly dried granules may form hard tablets with slow disintegration and dissolution, impacting the drug's bioavailability. Conversely, under-dried granules can lead to tablets that may disintegrate too quickly or inconsistently.
3. **Content Uniformity:** Inadequate drying can result in clumping or sticking, leading to uneven granulation and non-uniform distribution of the API within the tablet. Content uniformity is critical for ensuring that each tablet delivers the correct dose of the active ingredient.
4. **Stability:** Moisture can lead to the degradation of sensitive APIs, leading to chemical instability in the final product. Drying temperature control is therefore essential to achieving the right moisture level, which in turn ensures product stability during its shelf life. Excessive drying temperatures, on the other hand, can degrade heat-sensitive APIs or excipients, affecting product stability and potency.

D. Optimization of Drying Temperature

Optimal drying temperature is a balance between removing moisture efficiently while preserving the quality and integrity of the granules and API. Several strategies can help achieve this:

1. **Design of Experiments (DoE):** A systematic approach to varying drying temperature and time, alongside other process variables, helps to determine the optimal drying conditions that produce granules with the desired characteristics.
2. **Real-Time Monitoring (PAT):** **Process Analytical Technology (PAT)** tools such as near-infrared spectroscopy (NIR) or moisture sensors can be used during drying to monitor granule moisture content in real-time, allowing for precise control of the drying process. This helps avoid both under- and over-drying.
3. **Scale-Up Considerations:** Drying conditions in small-scale experiments may need adjustment during scale-up due to differences in equipment and batch size. Monitoring and control systems are essential during scale-up to ensure that drying temperature remains within optimal limits to maintain consistent product quality.

V. INTERPLAY BETWEEN GRANULATION TIME, DRYING TEMPERATURE, AND COMPRESSION PARAMETERS

The pharmaceutical manufacturing process is a complex system where different steps influence one another, particularly in the context of granulation time, drying temperature, and compression parameters. These Critical Process Parameters (CPPs) are interdependent, and their optimization is essential for ensuring the final product's quality, safety, and efficacy. Understanding their interplay is vital for controlling Critical Quality Attributes (CQAs), such as tablet hardness, disintegration time, dissolution rate, and content uniformity.

1. Granulation Time and Its Effect on Drying and Compression

- **Granulation time** directly affects the properties of the granules, such as particle size distribution, moisture content, and cohesion, all of which influence how these granules behave during drying and compression.
- **Granule Formation:** If the granulation time is too short, the granules may remain small, unevenly formed, or loosely agglomerated, which can lead to inconsistent moisture distribution and non-uniform drying. On the other hand, prolonged granulation time may create large, dense granules that retain excess moisture or are difficult to compress.
- **Impact on Drying:** Granules formed during the granulation process need to have the right moisture content. If the granulation time is too short, the smaller granules may dry unevenly, leading to inconsistent moisture removal. Excessively long granulation time can lead to dense granules that may require more drying time or higher temperatures to adequately reduce moisture.
 - **Short Granulation Time:** Leads to poor agglomeration, resulting in fine or small granules. These may dry faster but can cause uneven drying, leading to residual moisture in some particles.
 - **Long Granulation Time:** Produces large, cohesive granules that might require more drying time or higher temperatures. Over-drying may result in overly brittle granules, making them difficult to compress.
- **Impact on Compression:** Granulation time also determines the compressibility of the granules. Short granulation time may lead to weak, friable granules that produce soft tablets with poor mechanical properties. Prolonged granulation may create too hard granules, making compression difficult, leading to tablets that are too hard and have poor disintegration or dissolution profiles.

2. Drying Temperature and Its Impact on Compression Parameters

The drying temperature is critical for controlling the moisture content of granules, which in turn influences their flowability, compressibility, and mechanical strength during tablet compression.

- **Effect on Granule Moisture Content:** Drying temperature must be carefully controlled to ensure that the granules reach the optimal moisture content before compression. If the drying temperature is too low, excess moisture can remain in the granules, leading to sticking issues and poor compressibility during tablet formation. Conversely, if the drying temperature is too high, granules may become too dry, leading to brittleness, poor flowability, and difficulty in achieving uniform compression.
- **Impact on Compressibility:**
 - **Underdried Granules:** If drying temperature is insufficient, the granules may retain excess moisture, making them sticky. This can result in poor flow into the tablet die, leading to inconsistent tablet weight and difficulty achieving uniform hardness. Sticky granules may also cause equipment clogging and inefficiency during compression.
 - **Overdried Granules:** Excessively high drying temperatures can make granules too dry and brittle, affecting their ability to deform properly during compression. These overly dry granules may require higher compression forces, which can negatively affect the tablet's structural integrity, resulting in tablets that are too hard or prone to capping and lamination.
- **Granule Porosity:** Proper drying ensures that granules maintain a balance between porosity and density, which is essential for effective tablet compression. Over-dried or under-dried granules can lead to compression issues such as poor tablet compaction, variable hardness, or inconsistent disintegration times.

3. Interplay Between Granulation Time and Drying Temperature

The relationship between granulation time and drying temperature is significant in determining the overall characteristics of the granules, such as size, moisture content, and mechanical strength.

- **Granule Size Distribution:** Granulation time affects the granule size, and drying temperature must be adjusted accordingly to ensure uniform drying. Shorter granulation times result in smaller, more porous granules that may dry quickly but unevenly. Longer granulation times produce larger, denser granules that may require a higher drying temperature or longer drying duration. Therefore, optimal granulation time and drying temperature must be matched to ensure uniform granule size and moisture distribution.
- **Moisture and Granule Integrity:** Excessive granulation time combined with a high drying temperature can cause over-drying, making granules too hard or brittle. Conversely, a short granulation time with a low drying

temperature may leave residual moisture in the granules, leading to sticky, poorly flowing material that impacts compression. Hence, these two CPPs must be balanced to produce granules that have optimal moisture content and mechanical properties for downstream processing.

4. Effect of Compression Parameters on Granules Produced by Different Granulation and Drying Conditions

The compression parameters (e.g., compression force, tablet press speed) are directly influenced by the characteristics of granules produced by the interplay of granulation time and drying temperature.

- **Tablet Hardness and Compression Force:** Granules with high moisture content (due to insufficient drying) may require lower compression force, but the resulting tablets may be too soft and friable. Excessive drying, combined with prolonged granulation, may result in hard, brittle granules that require higher compression forces, leading to overly hard tablets that have poor disintegration and dissolution characteristics. Properly balanced granulation and drying parameters yield granules with optimal compressibility, allowing for the application of moderate compression forces that produce tablets with the desired hardness, mechanical stability, and dissolution rate.
- **Flowability and Die Filling:** Over-dried granules may become too light and dusty, leading to poor flowability, which affects die filling during compression and results in inconsistent tablet weight and API distribution. Conversely, under-dried granules may clump together, leading to uneven filling and variability in tablet weight. Granulation time and drying temperature need to be optimized together to ensure the granules flow smoothly into the dies, enabling consistent compression results.
- **Disintegration and Dissolution:** Tablets compressed from poorly dried or overly dried granules can show variability in disintegration time and dissolution rates, which are critical for ensuring bioavailability. The right balance between granulation time and drying temperature produces granules with uniform size, moisture content, and porosity, allowing the compression process to produce tablets that disintegrate and dissolve as intended.

VI. REGULATORY CONSIDERATIONS

In pharmaceutical manufacturing, controlling Critical Process Parameters (CPPs) and ensuring consistent Critical Quality Attributes (CQAs) are key to delivering safe, effective, and high-quality products. The regulatory framework provided by ICH Q8, ICH Q9, and ICH Q10 offers detailed guidance on managing these factors through a systematic, risk-based approach. Additionally, Process Analytical Technology (PAT) plays a crucial role in achieving real-time monitoring and control over these parameters, ensuring continuous process improvement and regulatory compliance.

A. ICH Guidelines: ICH Q8, Q9, and Q10

1. ICH Q8(R2) - Pharmaceutical Development

ICH Q8 focuses on **Quality by Design (QbD)** principles, emphasizing the importance of understanding and controlling CPPs and CQAs throughout the pharmaceutical development process. This guideline promotes a systematic approach to development, enabling manufacturers to design quality into their products by understanding how variability in CPPs affects CQAs.

Key principles from ICH Q8 include:

- **Identification of CPPs and CQAs:** The guideline stresses the need to identify and understand the relationship between CPPs (e.g., granulation time, drying temperature) and CQAs (e.g., tablet hardness, dissolution rate) early in the product development stage.
- **Design Space:** ICH Q8 introduces the concept of **design space**, which refers to the range of process parameters within which CQAs remain consistent. Understanding the design space allows manufacturers to operate within flexible limits, reducing the need for post-approval changes.
- **Risk Management and Process Optimization:** Manufacturers must assess how variations in CPPs (such as changes in granulation time or drying temperature) impact CQAs to ensure consistent product quality.

2. ICH Q9 - Quality Risk Management

ICH Q9 provides a framework for risk management in pharmaceutical manufacturing, emphasizing the need for identifying, assessing, and controlling risks associated with CPPs and CQAs. The principles of risk-based decision-making help manufacturers prioritize resources to areas with the highest risk to product quality and patient safety.

Key elements from ICH Q9:

- **Risk Assessment:** This process involves identifying potential risks related to process variability, such as changes in granulation or drying parameters, and assessing their impact on CQAs.
- **Risk Control:** Manufacturers must implement strategies to minimize or mitigate risks associated with CPPs that could adversely affect product quality.
- **Risk Review:** Continuous review of risk management strategies ensures that as processes evolve, the risks associated with CPPs and CQAs remain adequately controlled.

3. ICH Q10 - Pharmaceutical Quality System

ICH Q10 establishes a Pharmaceutical Quality System (PQS) framework, outlining how manufacturers should structure their quality systems to maintain control over CPPs and ensure product quality throughout the lifecycle.

Key components of ICH Q10 include:

- **Lifecycle Management:** ICH Q10 stresses continuous improvement in product quality over its lifecycle. Manufacturers are encouraged to monitor CPPs and CQAs not just during development but also after the product is on the market, using tools like PAT to adapt and improve processes.
- **Knowledge Management:** Manufacturers are expected to use data from development, manufacturing, and quality control processes to continuously update their understanding of CPPs and CQAs.
- **Change Management:** ICH Q10 provides guidance on managing changes to CPPs, ensuring that any adjustments are made in a controlled manner and that the impact on CQAs is thoroughly evaluated before implementation.

B. Process Analytical Technology (PAT) and Its Role in CPP Control

Process Analytical Technology (PAT), introduced by the U.S. FDA and endorsed by ICH guidelines, is a key tool for enabling real-time monitoring and control of CPPs and CQAs during pharmaceutical manufacturing. PAT allows for continuous, real-time data collection on critical processes, such as granulation and drying, helping manufacturers maintain control over key process parameters.

Role of PAT in Controlling CPPs and CQAs

1. Real-Time Monitoring:

- **Granulation Time:** PAT tools, such as near-infrared (NIR) spectroscopy and laser diffraction, can be used to monitor particle size distribution and moisture content during granulation. By measuring these attributes in real time, manufacturers can adjust the granulation process dynamically to achieve the desired granule characteristics (size, density, moisture content).
- **Drying Temperature:** PAT tools like moisture analyzers and NIR can continuously monitor the moisture content of granules during the drying process. This ensures that the granules reach the optimal moisture level for compression, avoiding issues like over-drying or under-drying.

Real-time monitoring allows manufacturers to detect process deviations early, minimizing the risk of off-specification products.

2. Process Control:

- **Closed-Loop Control:** PAT enables closed-loop systems where real-time data is fed back into the process control system. For example, if the granules during drying are found to retain too much moisture, the drying temperature or time can be adjusted automatically to bring the granules within the desired specification.
- **Reduced Variability:** PAT tools help in reducing variability in CPPs, leading to more consistent CQAs. For instance, continuous monitoring of granulation and drying conditions ensures that all granules receive uniform processing, reducing the risk of variability in tablet hardness or dissolution rates.

3. **Data-Driven Optimization:**

- **Design Space Expansion:** Using PAT tools during development allows manufacturers to understand the boundaries of their design space more comprehensively. By collecting real-time data on how variations in granulation and drying parameters affect CQAs, manufacturers can define broader, more flexible operating ranges while ensuring consistent quality.
- **Continuous Improvement:** PAT allows for ongoing process optimization after the product has been commercialized. Manufacturers can monitor processes in real-time and adjust parameters like granulation time and drying temperature based on live data, improving efficiency and reducing batch failures.

VII. CHALLENGES AND FUTURE DIRECTIONS IN OPTIMIZING GRANULATION, DRYING, AND COMPRESSION PROCESSES

In pharmaceutical manufacturing, balancing granulation and drying conditions is critical for ensuring product quality. However, optimizing these processes poses several challenges, from variability in material properties to limitations in real-time monitoring. Advancements in technology, such as continuous manufacturing and advanced simulation tools, are increasingly helping to address these challenges, while several promising areas for future research remain.

A. Challenges in Optimization

1. **Material Variability:**

- **API Sensitivity:** Different active pharmaceutical ingredients (APIs) and excipients can exhibit widely varying properties, including hygroscopicity, heat sensitivity, and compressibility. This makes it challenging to optimize a single set of granulation and drying conditions for different formulations. APIs that are highly sensitive to temperature or moisture pose a risk of degradation during drying, requiring precise control of process parameters.
- **Batch-to-Batch Variation:** Variability in raw material properties, such as particle size distribution and moisture content, can affect the granulation and drying processes, leading to inconsistent granule characteristics. This variation can make it difficult to maintain consistent product quality without frequent adjustments to process parameters.

2. **Process Interdependency:**

- **Balancing Granulation Time and Drying Temperature:** The interdependency between granulation time and drying temperature presents a challenge. For instance, shorter granulation times may produce smaller, less cohesive granules that dry quickly but may not compress well. Conversely, longer granulation times may require higher drying temperatures or longer drying durations, which could lead to granule brittleness or thermal degradation of the API.
- **Scale-Up Challenges:** Scaling up from laboratory-scale to commercial-scale production often introduces challenges in maintaining process consistency. Differences in equipment size, geometry, and heat transfer dynamics can impact the drying rate, granule moisture distribution, and the overall compressibility of the granules.

3. **Real-Time Monitoring Limitations:**

- **Insufficient Real-Time Data:** Although **Process Analytical Technology (PAT)** provides real-time monitoring, it can still be limited in certain processes. For example, precise real-time monitoring of internal granule moisture content or API distribution may not always be achievable with current technology. As a result, process optimization relies heavily on post-process quality checks, which can lead to delays in identifying and correcting deviations.
- **Dynamic Process Control:** Implementing a closed-loop control system where real-time data can automatically adjust parameters (such as drying temperature or compression force) remains a technical challenge. The ability to dynamically adjust granulation or drying conditions based on real-time feedback is not yet fully mature in many manufacturing environments.

B. Technological Advancements

1. Continuous Manufacturing:

- **Enhanced Process Control:** Continuous manufacturing offers several advantages over traditional batch processing, including the ability to monitor and adjust CPPs in real-time. In continuous wet granulation, for example, granules are formed and dried in a single, continuous process, allowing for real-time adjustments to be made to granulation time, moisture content, and drying temperature without disrupting the production flow. This reduces batch-to-batch variability and allows for a more consistent product output.
- **Efficiency and Flexibility:** Continuous processes can integrate inline PAT tools that monitor moisture content, particle size, and other CQAs, ensuring optimal process control. This helps manufacturers to quickly respond to any deviations in CPPs, improving efficiency and reducing waste. Additionally, continuous systems are more flexible, enabling manufacturers to produce smaller, more frequent batches and reduce lead times.

2. Advanced Simulation and Modeling Tools:

- **Computational Fluid Dynamics (CFD):** CFD and other advanced modeling tools are being increasingly used to simulate granulation and drying processes. These models can help manufacturers understand the complex heat and mass transfer mechanisms involved in drying granules, allowing them to optimize drying parameters such as airflow, temperature distribution, and drying time.
- **Mechanistic Modeling for Granulation:** Predictive models that simulate granule growth, aggregation, and breakage during wet granulation are now being developed. By using these models, manufacturers can optimize granulation time and liquid binder addition to achieve the desired granule size distribution and mechanical properties, leading to improved compressibility.
- **Digital Twins:** A digital twin is a virtual representation of the manufacturing process that can be used to simulate different scenarios and predict the impact of changing process parameters. By integrating real-time data from PAT tools, digital twins can help manufacturers optimize CPPs such as drying temperature and granulation time, and predict their impact on CQAs.

3. PAT and Automation:

- **Advanced PAT Tools:** New generations of PAT tools, including near-infrared (NIR) spectroscopy, Raman spectroscopy, and moisture analyzers, are becoming more sensitive and versatile. These tools enable real-time, non-destructive measurement of critical parameters such as moisture content, API distribution, and granule size, allowing for more precise process control during granulation and drying.
- **Automated Control Systems:** As part of the Industry 4.0 transformation, automated process control systems are being developed that can make real-time adjustments to granulation and drying parameters based on PAT feedback. These systems are capable of fine-tuning parameters such as drying air temperature, granulation speed, and liquid addition rate to maintain optimal conditions for compression and final product quality.

C. Future Research Areas

1. Real-Time Moisture Content Monitoring:

- While PAT tools are already improving moisture monitoring, future research could focus on developing more precise, non-invasive technologies for real-time moisture content analysis within individual granules during both granulation and drying processes. This would help ensure that granules are uniformly dried, preventing issues related to over-drying or under-drying, which impact compressibility and dissolution rates.

2. Granulation Mechanism and Modeling:

- **Mechanistic understanding of granulation:** Further research is needed into the fundamental mechanisms of wet granulation, especially regarding how granule formation, growth, and breakage are influenced by CPPs like granulation time and liquid binder concentration. This knowledge could lead to more predictive models for optimizing granulation conditions in real-time.
- **Hybrid Modeling Approaches:** Combining machine learning with traditional mechanistic models may provide a more holistic view of granule formation and drying, especially for formulations with complex APIs. This would allow manufacturers to better predict the behavior of granules under different process conditions.

3. **Enhanced Scale-Up Techniques:**

- Research is needed into better scaling-up techniques for granulation and drying processes, particularly to maintain consistency between lab-scale and commercial-scale operations. This could involve the development of scale-independent models or improved heat transfer and moisture removal techniques that can be applied across different scales of production.

4. **Continuous Monitoring of API Distribution:**

- API distribution within granules is critical for ensuring uniform content in tablets, yet real-time monitoring of API distribution during granulation is still challenging. Future research could focus on developing better inline or real-time monitoring technologies for detecting and correcting non-uniform API distribution before the drying or compression steps.

5. **Integrated Digital Twins and AI:**

- Further development of **digital twins** for pharmaceutical processes is a promising research area. These virtual simulations, coupled with artificial intelligence (AI) and machine learning, can predict how changes in CPPs will impact CQAs and suggest real-time adjustments to optimize the process. Such systems would significantly enhance process understanding and optimization efforts, leading to reduced variability and improved product quality.

VIII. CONCLUSION

This review has elucidated the profound effects of granulation time and drying temperature on compression parameters and overall product quality in pharmaceutical manufacturing. The findings underscore the intricate relationship between these Critical Process Parameters (CPPs) and their consequent impact on Critical Quality Attributes (CQAs). Granulation Time an optimal granulation time is crucial for achieving the desired granule size, moisture content, and cohesiveness. Insufficient granulation can lead to poorly agglomerated granules that exhibit inadequate compressibility, while excessive granulation can produce overly dense granules that complicate subsequent processing steps. Drying Temperature the drying temperature significantly influences the moisture content and physical characteristics of granules. Inadequate drying can result in excessive moisture retention, leading to challenges in flowability and compression, whereas excessively high temperatures can cause brittleness and degradation of the active pharmaceutical ingredient (API). Interdependency of CPPs the interplay between granulation time and drying temperature is vital for optimizing granule properties. Balancing these parameters ensures uniform moisture content and mechanical characteristics, which directly impacts compressibility and final product quality. Impact on Compression Parameters the characteristics of granules formed during granulation and drying are critical determinants of tablet quality attributes such as hardness, dissolution rate, and content uniformity. Therefore, optimizing these processes is essential for producing high-quality tablets that meet regulatory standards. The optimization of CPPs and CQAs is imperative for ensuring patient safety, therapeutic efficacy, and regulatory compliance. Manufacturers must prioritize the careful management of granulation and drying conditions to maintain consistent product quality while enhancing manufacturing efficiency. Advancements in technologies, including continuous manufacturing and Process Analytical Technology (PAT), offer promising avenues for achieving real-time monitoring and control, further supporting the optimization efforts in pharmaceutical manufacturing. In conclusion, understanding and optimizing the effects of granulation time and drying temperature on compression parameters is essential for the pharmaceutical industry. By implementing systematic approaches to process design and control, manufacturers can ensure the production of safe, effective, and high-quality therapeutic products that fulfill patient needs and regulatory expectations.

REFERENCE:

- [1] Engisch W.E., Muzzio F.J. Loss-in-weight feeding trials case study: Pharmaceutical formulation. *J. Pharm. Innov.* 2015;10:56–75. doi: 10.1007/s12247-014-9206-1.
- [2] FDA, Guidance for industry: PAT – A framework for innovative pharmaceutical development, manufacturing and quality assurance. 2004.
- [3] FDA, Guidance for industry: Pharmaceutical CGMPs For the 21st Century – A Risk-Based Approach, Final Report. 2004.
- [4] Fell J., Newton J. Determination of tablet strength by the diametral-compression test. *J. Pharm. Sci.* 1970;59:688–691. doi: 10.1002/jps.2600590523
- [5] Fisher A.C., Liu W., Schick A., Ramanadham M., Chatterjee S., Brykman R., Lee S.L., Kozlowski S., Boam A.B., Tsinontides S. An Audit of Pharmaceutical Continuous Manufacturing Regulatory Submissions and Outcomes in the US. *Int. J. Pharm.* 2022;622:121778. doi: 10.1016/j.ijpharm.2022.121778.
- [6] Franke M., Riedel T., Meier R., Schmidt C., Kleinebudde P. Comparison of scale-up strategies in twin-screw wet granulation. *Int. J. Pharm.* 2023;641:123052. doi: 10.1016/j.ijpharm.2023.123052.
- [7] Gamble J.F., Dennis A.B., Tobyn M.: *Pharm. Dev. Technol.*
- [8] Ganguly S., Gao J.Z.: Application of focused beam reflectance measurement technology in high-shear wet granulation, AAPS 2005 General Meeting, Nashville TN; AAPS J. 7(S2), Abstract No. T3216 (2005).
- [9] Haser A., Kittikunakorn N., Dippold E., DiNunzio J.C., Blincoe W. Continuous Twin-Screw wet granulation process with In-Barrel drying and NIR setup for Real-Time Moisture Monitoring. *Int. J. Pharm.* 2023;630:122377. doi: 10.1016/j.ijpharm.2022.122377.
- [10] Hassanpour A., Kwan C.C., Ng B.H., Rahmanian N., Ding Y.L., Antony S.J., Jia X.D., Ghadiri M.: *Powder Technol.* 189, 304 (2009).
- [11] Holman J., Tantuccio A., Palmer J., van Doninck T., Meyer R. A very boring 120 h: 15 million tablets under a continuous state of control. *Powder Technol.* 2021;382:208–231. doi: 10.1016/j.powtec.2020.12.073.
- [12] ICH Harmonised Guideline Continuous Manufacturing of Drug Substances and Drug Products. Q13. Final Version. Adopted on 16 November. ICH 2022. [(accessed on 10 September 2023)].
- [13] ICH: Q8 Pharmaceutical development. 2008.
- [14] Iveson S.M. Litster J.D., Hapgood, K., Ennis B.J.: *Powder Technol.* 117, 3 (2001).
- [15] Karttunen A.-P., Wikström H., Tajarobi P., Fransson M., Sparén A., Marucci M., Ketolainen J., Folestad S., Korhonen O., Abrahmsén-Alami S. Comparison between integrated continuous direct compression line and batch processing—The effect of raw material properties. *Eur. J. Pharm. Sci.* 2019;133:40–53. doi: 10.1016/j.ejps.2019.03.001.
- [16] Keleb E., Vermeire A., Vervaet C., Remon J.P. Twin screw granulation as a simple and efficient tool for continuous wet granulation. *Int. J. Pharm.* 2004;273:183–194. doi: 10.1016/j.ijpharm.2004.01.001.
- [17] Kemp I.C., Iler L., Waldron M., Turnbull N. Modeling, experimental trials, and design space determination for the GEA ConsiGma™ coater. *Dry. Technol.* 2019;37:475–485. doi: 10.1080/07373937.2018.1463244.

- [18] Kiricenko K., Kleinebudde P. Drying behavior of a horizontal vibrated fluidized bed dryer for continuous manufacturing. *Pharm. Dev. Technol.* 2023;28:440–451. doi: 10.1080/10837450.2023.2205932.
- [19] Leane M., Pitt K., Reynolds G.K., Dawson N., Ziegler I., Szepes A., Crean A.M., Dall Agnol R., Group M.C.S.W. Manufacturing classification system in the real world: Factors influencing manufacturing process choices for filed commercial oral solid dosage formulations, case studies from industry and considerations for continuous processing. *Pharm. Dev. Technol.* 2018;23:964–977. doi: 10.1080/10837450.2018.1534863.
- [20] Lee S.L., O'Connor T.F., Yang X., Cruz C.N., Chatterjee S., Madurawe R.D., Moore C., Yu L.X., Woodcock J. Modernizing pharmaceutical manufacturing: From batch to continuous production. *J. Pharm. Innov.* 2015;10:191–199. doi: 10.1007/s12247-015-9215-8.
- [21] Megarry A.J., Swainson S.M., Roberts R.J., Reynolds G.K. A big data approach to pharmaceutical flow properties. *Int. J. Pharm.* 2019;555:337–345. doi: 10.1016/j.ijpharm.2018.11.059.
- [22] Montgomery D.C.: Design and Analysis of Experiments, 6th edn., J. Wiley & Sons, Inc., Hoboken NJ 2005.
- [23] Parikh D.M.: Handbook of pharmaceutical granulation technology, Marcel Dekker, New York 1997.
- [24] Portier C., Vervaet C., Vanhoorne V. Continuous twin screw granulation: A review of recent progress and opportunities in formulation and equipment design. *Pharmaceutics*. 2021;13:668. doi: 10.3390/pharmaceutics13050668.
- [25] PQRI: Process robustness ñ a PQRI white paper, *Pharm. Eng.* 26, 1 (2006).
- [26] Rantanen J., Rönönen E., Tenhunen J., Kouskoski M., Mannermaa J.-P., Yliruusi J.: *Eur. J. Pharm. Biopharm.* 50, 271 (2000).
- [27] Rosas J.G., Brush P., Thompson B., Miller C., Overton P., Tugby N., Stoliarskaia D., Hurley S., Ramasamy M., Conway S.L. Implementation of a fully integrated CM direct compression and coating process at a commercial pharmaceutical facility—Part 2: PAT and RTD results for normal operational conditions batches. *Int. J. Pharm.* 2023;636:122814. doi: 10.1016/j.ijpharm.2023.122814.
- [28] Ryckaert A., Ghijs M., Portier C., Djuric D., Funke A., Vervaet C., De Beer T. The influence of equipment design and process parameters on granule breakage in a semi-continuous fluid bed dryer after continuous twin-screw wet granulation. *Pharmaceutics*. 2021;13:293. doi: 10.3390/pharmaceutics13020293.
- [29] Spring M.S.: *Drug Dev. Ind. Pharm.* 9, 1507 (1983).
- [30] Staniforth J.N., Quincey S.M.: *Int. J. Pharm.* 32, 177 (1986).
- [31] Terashita K., Watano S., Miyanami K.: *Chem. Pharm. Bull.* 38, 3120 (1990).
- [32] Teunou E., Poncelet D. Batch and continuous fluid bed coating—Review and state of the art. *J. Food Eng.* 2002;53:325–340. doi: 10.1016/S0260-8774(01)00173-X.
- [33] Thompson M. Twin screw granulation—Review of current progress. *Drug Dev. Ind. Pharm.* 2015;41:1223–1231. doi: 10.3109/03639045.2014.983931.
- [34] Vercruysse J., Delaet U., Van Assche I., Cappuyns P., Arata F., Caporicci G., De Beer T., Remon J.P., Vervaet C. Stability and repeatability of a continuous twin screw granulation and drying system. *Eur. J. Pharm. Biopharm.* 2013;85:1031–1038. doi: 10.1016/j.ejpb.2013.05.002.

[35] Woodcock J. Modernizing pharmaceutical manufacturing—continuous manufacturing as a key enabler; Proceedings of the MIT-CMAC International Symposium on Continuous Manufacturing of Pharmaceuticals; Cambridge, MA, USA. 20 May 2014.

[36] Yu L.X.: Pharm. Res. 25, 781 (2008).

